Genmab A/S (NASDAQ:GMAB) Posts Earnings Results, Misses Expectations By $0.03 EPS

by · The Cerbat Gem

Genmab A/S (NASDAQ:GMAB – Get Free Report) issued its earnings results on Wednesday. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03), Zacks reports. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The firm had revenue of $816.10 million during the quarter, compared to analysts’ expectations of $838.20 million. During the same quarter last year, the business earned $0.47 EPS. Genmab A/S updated its FY 2024 guidance to EPS.

Genmab A/S Stock Performance

NASDAQ GMAB traded up $0.78 during mid-day trading on Thursday, reaching $23.11. 1,266,500 shares of the stock were exchanged, compared to its average volume of 670,717. Genmab A/S has a 1 year low of $21.90 and a 1 year high of $32.89. The business’s 50 day moving average is $24.57 and its 200-day moving average is $26.47. The company has a market capitalization of $15.29 billion, a P/E ratio of 19.04, a P/E/G ratio of 0.68 and a beta of 0.99.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Royal Bank of Canada raised Genmab A/S from a “sector perform” rating to an “outperform” rating in a report on Monday, July 15th. Redburn Atlantic initiated coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating on the stock. Truist Financial decreased their price objective on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, September 9th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Wednesday, October 16th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $31.00 target price on shares of Genmab A/S in a report on Wednesday, September 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $45.20.

Read Our Latest Stock Analysis on Genmab A/S

About Genmab A/S

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

See Also